Coenzyme Q10 in Huntington’s Disease (HD)

Huntington disease

Impatients N.V. trading as myTomorrows – SR aGvHD

Efficacy of Cognitive Rehabilitation Using Virtual Reality and Computer-based Cognitive Stimulation on Cognitive Impairment Associated to Movement Disorders Prospective Single-Timepoint Huntington’s Disease Biospecimen Collection Study A Pilot Study of Nutritional Status in Patients With Huntington’s Disease A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington’s Disease Development of the Virtual Unified Huntington’s Disease Rating Scale PhI/II Dose-Finding Study to Evaluate BV-101 Striatal Administration in Adults With Early Manifest Huntington’s Disease Clinicopathological MRI and CSF Correlates in Huntington’s Disease. A Randomised Controlled Trial, Of N-Acetyl Cysteine (NAC), for Premanifest Huntingtin Gene Expansion Carriers Efficacy and Safety on SOM3355 in Huntington’s Disease Chorea Comparison Between [11C]UCB-J and [18F]SynVest-1 PET in HD. A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington’s Disease (HD) A Study to Evaluate the Effect of SAGE-718 on Functioning Capacity in Participants With Huntington’s Disease Home-based Transcranial Direct Current Stimulation Open Trial for Behavioral and Cognitive Symptoms in Huntington’s Disease Making HD Voices Heard Pilot Study Move to Improve: Telehealth Exercise to Music for HD Energy Balance in Huntington’s Disease. A Multidisciplinary Study Approach for a Complex Problem (BEHD-EM) Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntington Disease Dosimetry of [11C]CHDI-180R and [11C]CHDI-626. N- Homocysteinylated Huntingtin in Huntington’s Disease Group Drum-Based Music Therapy Intervention for Parkinson’s Disease/Huntington’s Disease Measurement and Modification of Threat Interpretation Bias in Neurodegenerative Movement Disorders (Aims 2 & 3) A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington’s Disease (HD) Study of WVE-003 in Patients With Huntington’s Disease Adapted Physical Activity Effect on Abilities and Quality of Life of Huntington Patients and Relatives During Rehab Stay Safety and Tolerability Study With VY-HTT01, in Adults With Early Manifesting Huntington’s Disease TEsting METformin Against Cognitive Decline in HD Preparing for Prevention of Huntington’s Disease (PREVENT-HD) Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease Synaptic Density and Progression of Huntington’s Disease. Characterization and Quantification of Motor Speech Disorders in Huntington’s Disease: Identification of Acoustic Markers Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington’s Disease Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington’s Disease Assessing the Symptomatic Benefit of Acoustic Slow Wave Enhancement in Parkinson Disease PRidopidine’s Outcome On Function in Huntington Disease, PROOF- HD Mitochondrial Biomarkers in Huntington’s Disease An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington’s Disease Trial of the Combined Use of Thiamine and Biotin in Patients With Huntington’s Disease Melatonin for Huntington’s Disease (HD) Gene Carriers With HD Related Sleep Disturbance – a Pilot Study Non-invasive Brain Stimulation in Huntington’s Disease Natural History Study in Huntington Disease Gene Expansion Carriers (HDGECs) – SHIELD HD Biological Sample Collection for Research and Biobanking Treating Sleep/Wake Cycle Disturbances in Basal Ganglia Disorders With Ramelteon A Biospecimen and Clinical Data Study on Patients With Alzheimer’s, Multiple Sclerosis, Parkinson’s, and Huntington’s, for Drug & Biomarker Discovery Memory Disorders Registry Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies Electronic-health Application To Measure Outcomes REmotely Clinical Trial A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function Using Wearable and Mobile Data to Diagnose and Monitor Movement Disorders Laughter Therapy Effects on Mood, Stress and Self-efficacy in People With Neurological Diseases. OCTA in Mild Cognitive Impairment and Alzheimer’s Disease A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers Evaluating the Relationship of Morphine Consumption and Pain-related Molecules in Hepatic Surgical Patients CKD-504 in SAD and MAD in Healthy Korean and Caucasian Adult Male and Female Subjects Escalating Dose Study in Healthy Volunteers With SEN0014196 Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 in Healthy Young Male Volunteers Cognitive Assessment Battery (CAB) Beta Study A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine) Study of Motor Slowing in Parkinson’s Disease by a Computerized Mental Chronometry Paradigm Prospective Huntington At Risk Observational Study Individuals Patterns of Disclosure About Huntington s Disease (HD) and the Association With Adaptation to HD A Repeat Dose Study in Healthy Volunteers Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK356278 Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects. Creatine Safety and Tolerability in Premanifest HD: PRECREST Measuring Cortisol Levels in Persons With Parkinson’s (PD) Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 “After Multiple Oral Doses” in Healthy Volunteers Safety and Efficacy of Bone Marrow Derived MNCs for Treatment of Cells for the Treatment of Hunting Tons Chorea. Efficacy and Safety of Tetrabenazine in Chorea FuRST 2.0 Cognitive Pre-testing – Round 2 Citalopram to Enhance Cognition in HD Cooperative Huntington’s Observational Research Trial A Phase II Safety and Tolerability Study With SEN0014196 FuRST 2.0 Cognitive Pre-Testing Far Infrared Irradiation for Managing, Control and Treatment of Huntington’s Disease (HD) Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated With HD Dance and Huntington Disease Feasibility and Acceptability of Implementing a Clinic-based Physical Activity Coaching Intervention in People With Premanifest and Early Stage HD iMagemHTT: FIH Evaluation of Novel Mutant Huntingtin PET Radioligands [¹¹C]CHDI-00485180-R and [¹¹C]CHDI-00485626 Healthy Volunteer Positron Emission Tomography (PET) Brain Occupancy Study of a Phosphodiesterase 4 (PDE4) Inhibitor in Huntington’s Disease Proof of Concept of an Anaplerotic Study Using Brain Phosphorus Magnetic Resonance Spectroscopy in Huntington Disease Long-Term Study of Cerebral Glucose Metabolism in Huntington’s Disease A Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO7234292 (RG6042) in CSF and Plasma, and Safety and Tolerability Following Intrathecal Administration in Patients With Huntington’s Disease Development of Assessments for Later Stage HD 31P-MRS and Huntington Disease Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington Disease A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington’s Disease Treadmill Walking in Individuals With Dementia With Lewy Bodies and Huntington’s Disease Is Caffeine an Environmental Modifier in Huntington’s Disease? Treatment of Huntington’s Chorea With Amantadine Apathy Cure Through Bupropion in Huntington’s Disease Clinical Study to Monitor Plasma Levels of 24OHC in Subject With HD Nilotinib in Huntington’s Disease Assessing Efficacy of Neuropsychiatric Assessment and Treatment Protocols in Huntington’s Disease Patients Decoding Presymptomatic White Matter Changes in Huntington Disease Multicentric Trial of the Treatment of Huntington’s Disease by Cysteamine (RP103) Atomoxetine and Huntington’s Disease A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington’s Disease – Part B An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington’s Disease Patients Who Participated in Prior Roche and Genentech Sponsored Studies Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease MIG-HD: Multicentric Intracerebral Grafting in Huntington’s Disease PHysical Activity and Exercise Outcomes in Huntington’s Disease Deep Brain Stimulation (DBS) of the Globus Pallidus (GP) in Huntington’s Disease (HD) [PETDE10] Imaging of PDE10A Enzyme Levels in Huntington’s Disease Gene Expansion Carriers and Healthy Controls With PET. Follow-up Measurement of Brain PDE10A Enzyme Levels in Huntington´s Disease Gene Expansion Carriers Riluzole in Huntington’s Disease Functional Imaging of Social Cognition in Premanifest Huntington’s Disease Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington’s Disease Patients Clinical Extension Study for Safety and Efficacy Evaluation of Cellavita-HD Administration in Huntington’s Patients. Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington’s Disease A Study in Subjects With Late Prodromal and Early Manifest Huntington’s Disease (HD) to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Pepinemab (VX15/2503) A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease A Pilot Evaluation of Mindfulness-based Cognitive Therapy for People With Huntington’s Disease Safety and Efficacy of OMS643762 in Subjects With Huntington’s Disease Study in PRE-manifest Huntington’s Disease of Coenzyme Q10 (UbiquinonE) Leading to Preventive Trials (PREQUEL) An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease Resveratrol and Huntington Disease Safety and Tolerability of WVE-120102 in Patients With Huntington’s Disease Safety and Tolerability of WVE-120101 in Patients With Huntington’s Disease Effect of Tetrabenazine on Stroop Interference in HD Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and Tiapride Study of Memantine to Treat Huntington’s Disease HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington’s Disease Social Cognition in Huntington’s Disease: Cognitive Study and Functional and Morphological Imaging Effects of EGCG (Epigallocatechin Gallate) in Huntington’s Disease (ETON-Study) Making Sense of a Positive Genetic Test Result for Huntington Disease Safety and Efficacy of Fenofibrate as a Treatment for Huntington’s Disease Minocycline in Patients With Huntington’s Disease Exploring Computerised Cognitive Training for People With Huntington’s Disease Effects of Lithium and Divalproex`on Brain-Derived Neurotrophic Factor in Huntington’s Disease Behavioural Problems in Huntington Disease : Analysis and Enhancement of Caregiver and Patient Experience A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington’s Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139) Metabolomic Study in Huntington’s Disease (METABO-HD) Creatine Safety, Tolerability, & Efficacy in Huntington’s Disease (CREST-E) Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington’s Disease A Pre-Cellular Therapy Observational Study in Early Huntington’s Disease A Clinical Study in Participants With Huntington’s Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington’s Disease Deep Brain Stimulation of the Globus Pallidus in Huntington’s Disease Safety and Tolerability Study of Phenylbutyrate in Huntington’s Disease (PHEND-HD) Huntington’s Disease 123 Utilization of 31P-Nuclear Magnetic Resonance Spectroscopy to Monitor Brain Energy Deficit in Huntington Disease Examination of Quantitative Electroencephalographic (QEEG) Biomarkers in Huntington’s Disease Ursodiol in Huntington’s Disease The Effect of Video Game Exercise on Dynamic Balance and Gait in Individuals With Huntington’s Disease A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease Working Memory Training in Huntington’s Disease A Pilot Study Assessing Impulsivity in Patients With Huntington’s Disease on Xenazine (Tetrabenazine) Risperidone for the Treatment of Huntington’s Disease Involuntary Movements Accelerated Diffusion MRI for Diagnosis of Hungtington Disease A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington’s Disease Safety Evaluation of Cellavita HD Administered Intravenously in Participants With Huntington’s Disease Symptomatic Therapy for Patients With Huntington’s Disease Effects of Music Therapy on Huntington’s Disease Wearable Sensors for Quantitative Assessment of Motor Impairment in Huntington’s Disease Huntington’s Disease Bioavailability of Ubiquinol in Huntington Disease Efficacy and Safety of SOM3355 in Huntington’s Disease Chorea Creatine Therapy for Huntington’s Disease REGISTRY – an Observational Study of the European Huntington’s Disease Network (EHDN) Child to Adult Neurodevelopment in Gene Expanded Huntington’s Disease Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington’s Disease Coenzyme Q10 in Huntington’s Disease (HD) Premanifest Huntington’s Disease Extension Study II: Creatine Safety & Tolerability Creatine Safety & Tolerability in Huntington’s Disease HD-Charge: Indirect and Out-of-Pocket Costs of Huntington’s Disease in the United States TREND-HD – A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington’s Disease Feasibility of a Video-oculography in Patients With Huntington’s Disease VOG-HD Study Neurobiological Predictors of Huntington’s Disease (PREDICT-HD) Premanifest Huntington’s Disease: Creatine Safety & Tolerability Extension Study Exercise Effects in Huntington’s Disease A Study of Treatment With Pridopidine (ACR16) in Patients With Huntington’s Disease A Study of Pridopidine (ACR16) for the Treatment of Patients With Huntington’s Disease Deep Brain Stimulation Treatment for Chorea in Huntington’s Disease PINS Stimulator System for Deep Brain Stimulation in Huntington’s Disease A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington’s Disease Neuroprotection by Cannabinoids in Huntington’s Disease Study of Biomarkers That Predict the Evolution of Huntington’s Disease Family Health After Predictive Huntington Disease (HD) Testing Dose-response Evaluation of the Cellavita HD Product in Patients With Huntington’s Disease Beta Testing of a New Assessment in Huntington’s Disease (HD) Study of BDNF Pathway Biomarkers in the Cerebrospinal Fluid in Patients With Huntington’s Disease Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington’s Disease Efficacy, Safety and Tolerability of AFQ056 in Patients With Huntington’s Disease in Reducing Chorea Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington’s Disease Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington’s Disease A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington Disease An Exploratory Clinical Trial in Early Stage Huntington’s Disease Patients With SEN0014196 Pilot Study of Minocycline in Huntington’s Disease Characterization of the Profile of Dysarthria in Huntington’s Disease, Using the Clinical Evaluation Battery of Dysarthria Couple and Spouse Caregiver in Huntington’s Disease A Study of the Novel Drug Dimebon in Patients With Huntington’s Disease Study of Huntington Patients in Connection With European Huntington’s Disease Network (EHDN)